Drugs / Irinotecan Liposome Injection
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT07235202 Background | Dec 2025 → Jun 2028 expected | pancreatic ductal adenocarcinoma | Shenzhen Majory Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Irinotecan Liposome Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07235202 ↗ |